Linden Lake Venture Capital

Linden Lake Ventures invest in the next generation of biotechnology companies bringing transformative new molecular medicines to patients in need. Our approach is hands-on and our focus is on early-stage (pre-clinical/phase I) technologies.

Thomas Haag Ph.D

Managing Partner

1 past transactions

Vesigen Therapeutics

Series A in 2020
Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.